Chemical Component Summary

Identifiers (4S,5R,6R)-5-acetamido-4-(diaminomethylideneamino)-6-[(1R,2R)-1,2,3-trihydroxypropyl]-5,6-dihydro-4H-pyran-2-carboxylic acid
Formula C12 H20 N4 O7
Molecular Weight 332.31  g/mol
Isomeric SMILES CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O)N=C(N)N
InChI InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1

Chemical Details

Formal Charge 0
Atom Count 43
Chiral Atom Count 5
Chiral Atoms C4 C5 C6 C7 C8
Bond Count 43
Aromatic Bond Count 0
Leaving Atoms n/a

Drug Info: DrugBank

DrugBank ID DB00558   (Stereoisomeric match)
Name Zanamivir
  • approved
  • investigational
Description A guanido-neuraminic acid that is used to inhibit neuraminidase. [PubChem]
  • (2R,3R,4S)-3-(acetylamino)-4-Carbamimidamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
  • 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid
  • 4-Guanidino-neu5ac2en
  • 5-(acetylamino)-2,6-Anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid
  • 5-acetamido-2,6-Anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid
Brand Names Relenza
Affected Organism
  • Influenza A virus
  • Influenza B virus
Indication For the prevention and treatment of influenza A and B.
Pharmacology Zanamivir, an antiviral agent, is a neuraminidase inhibitor indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients 7 years and older who have been symptomatic for no more than 2 days. Zanamivir has also been shown to significantly inhibit the human sialidases NEU3 and NEU2 in the micromolar range (Ki 3.7 +/-0.48 and 12.9+/-0.07 microM, respectively), which could account for some of the rare side effects of zanamivir.
Mechanism of action The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. By binding and inhibiting the neuraminidase protein, the drug renders the influenza virus unable to escape its host cell and infect others.
Route of administration
  • inhalation; oral
  • respiratory (inhalation)
  • Antiviral Agents
  • Enzyme Inhibitors
ATC-Code J05AH01
AHFS-Code 08:18.28
CAS number 139110-80-8
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682